Medicenna Expands MDNA11 into Neoadjuvant Melanoma with NEO-CYT Trial
Event summary
- First patient dosed in NEO-CYT Phase 1b trial evaluating MDNA11 in neoadjuvant melanoma.
- Trial sponsored by Fondazione Melanoma Onlus, led by Professor Paolo A. Ascierto.
- MDNA11 combined with nivolumab, with or without ipilimumab, in high-risk Stage III melanoma.
- Primary endpoint: major pathologic response, predictive of long-term survival.
- NEO-CYT expands MDNA11's evaluation beyond metastatic setting of ongoing ABILITY-1 study.
The big picture
Medicenna's NEO-CYT trial marks a strategic shift into earlier-stage melanoma, where neoadjuvant immunotherapy has shown potential for higher cure rates. The study builds on MDNA11's prior activity in metastatic settings, testing its ability to enhance immune responses before surgical intervention. Success could position Medicenna as a key player in personalized melanoma treatment, though competition remains intense with established checkpoint inhibitors and emerging IL-2 variants.
What we're watching
- Clinical Efficacy
- Whether MDNA11 can demonstrate superior pathologic response rates compared to existing neoadjuvant therapies.
- Regulatory Pathway
- The pace at which NEO-CYT data could support accelerated approval or expand MDNA11's indications.
- Competitive Positioning
- How Medicenna differentiates MDNA11 in the crowded IL-2 Superkine space.
Related topics